Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Louise Nash is a corporate partner based in Covington's London office.

Ms. Nash has over 20 years’ experience of global acquisitions and divestitures for emerging and mature companies as well as complex commercial transactions including joint ventures and licensing transactions. Her practice is international, with virtually all transactions upon which she advises having a cross-border dimension, and she has led global restructuring transactions, including both pre-merger separation and post-merger integration projects in over 100 jurisdictions. As such, she has extensive experience of dealing with the challenges presented by complex cross-border projects. She has particular experience in the branded goods, life sciences, and technology sectors. Ms. Nash has been recognized by leading directories, including as “Best in M&A” by LMG Euromoney on several occasions, and served on the firm’s Management Committee.

  • Advising Renesas Electronics Corporation on its €4.9 billion acquisition of Dialog Semiconductor plc.
  • Advising Eaton in its pending $2.83 billion acquisition of Cobham Mission Systems (CMS).
  • Representing Elanco in connection a series of antitrust-mandated divestitures in preparation for the $7.6 billion acquisition of Bayer Animal Health. These include an agreement with French pharmaceutical company Vetoquinol to divest the European Economic Area, UK, Canadian and Australian rights to the Drontal and Profender product families for US$150 million as well as an agreement with Merck Animal Health to divest the worldwide rights to Elanco's Vecoxan product for $55 million and divestiture of a number of development products.
  • Merck in its:
    • the global separation of its Organon business in preparation for the $6.5bn spin off of its women's health business;
    • €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions, the fastest growing part of the animal health industry; and
    • multi-year global merger integration with Schering-Plough.
  • Qualcomm Inc. on various European acquisitions including:
    • its $2.5bn recommended cash offer for CSR plc;
    • the purchase of assets in a UK-based 450 MHz handset design and manufacturing company;
    • the acquisition of Elata Holdings Limited; and
    • the acquisition of Trigenix Limited.
  • Eli Lilly’s Elanco Animal Health division on a number of cross-border transactions including:
    • the sale of its Dundee animal vaccines plant to Argenta Ltd; and
    • the sale of its Posilac business and manufacturing plant in Augusta, Georgia, to Brazilian company Union Agener.
  • Giorgio Armani S.p.A. on numerous international transactions including:
    • the acquisition of its retail and wholesale business in the United Kingdom from long-term retail partner Club 21;
    • a collaboration with a listed Dubai property company for the development of a worldwide chain of Armani hotels and resorts;
    • a joint venture with an Indian property consortium for the import, sale and distribution of Armani branded goods in India; and
    • the re-purchase of a 50% equity stake in the A/X Armani Exchange brand and the related global licensing and retail arrangements.
  • WTR1000, Transactions (2015-2016)
  • Euromoney Legal Media Group, Europe Women in Business Law AwardsWinner for M&A (2015-2017)  
  • Euromoney Legal Media Group, shortlisted for Europe Women in Business Law Awards for M&A (2014, 2018)
  • The Lawyer Hot 100 (2014)
  • Chambers UK, Private Equity, Venture Capital Investment (2009-2020)
  • Legal 500 UK, M&A: Lower Mid-Market Deals £50M-£500M (2021)
  • Legal 500 UK, Commercial Contracts (2015-2016)
  • Legal 500 UK, Venture Capital (2008-2016)
  • Legal 500 UK, Media and Entertainment (2008-2015)
  • Legal 500 UK, Pharmaceuticals & Biotechnology (2009)
  • Best Lawyers in the United Kingdom, Venture Capital Law (2014)
  • Super Lawyers - London, Corporate Finance (2013)
  • The Practical Law Company (PLC) Which Lawyer? England - Venture Capital (2008-2012)
  • IFLR European Awards 2015 - shortlisted in Deals of the Year: M&A